Cargando…

The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor

Studies assessing the effect and mechanism of probiotics on diseases of the upper gastrointestinal tract (GI) including gastric ulcers are limited despite extensive work and promising results of this therapeutic option for other GI diseases. In this study, we investigated the mechanisms by which the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dharmani, Poonam, De Simone, Claudio, Chadee, Kris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590171/ https://www.ncbi.nlm.nih.gov/pubmed/23484048 http://dx.doi.org/10.1371/journal.pone.0058671

Ejemplares similares

Correction: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2022)

Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020)

Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
por: Sang, Li-Xuan
Publicado: (2021)

Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(−/−) mice
por: Chan, Yee Kwan, et al.
Publicado: (2016)

Tumor Necrosis Factor-α and Muc2 Mucin Play Major Roles in Disease Onset and Progression in Dextran Sodium Sulphate-Induced Colitis
por: Dharmani, Poonam, et al.
Publicado: (2011)

Probiotic mixture VSL#3 prevents ulcerative colitis-associated carcinogenesis in mice and cells by regulating the inflammatory and Wnt/β-catenin pathway
por: Li, Wenbin, et al.
Publicado: (2022)

Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
por: Rashid, Sherzad K., et al.
Publicado: (2014)

Correction: Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
Publicado: (2014)

Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

The Probiotic Mixture VSL#3 Dampens LPS-Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1 Phosphorylation
por: Mariman, Rob, et al.
Publicado: (2014)

The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner
por: Isidro, Raymond A., et al.
Publicado: (2014)

Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
por: Wang, Chun-Sai-Er, et al.
Publicado: (2018)

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
por: Dang, Xiaofei, et al.
Publicado: (2020)

Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice
por: Theriot, Casey, et al.
Publicado: (2022)

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

PReS-FINAL-2074: The role of the probiotic VSL-3 as adjuvant therapy in patients with undifferentiated spondyloarthritis (ERA)
por: Vidovic, M, et al.
Publicado: (2013)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
por: Distrutti, Eleonora, et al.
Publicado: (2013)

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
por: Arthur, Janelle C., et al.
Publicado: (2013)

Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation
por: Kim, Seong-Eun, et al.
Publicado: (2015)

Administration of obestatin accelerates the healing of chronic gastric ulcers in rats
por: Dembiński, Artur, et al.
Publicado: (2011)

Development of omics‐based protocols for the microbiological characterization of multi‐strain formulations marketed as probiotics: the case of VSL#3
por: Mora, Diego, et al.
Publicado: (2019)

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
por: Boonma, Prapaporn, et al.
Publicado: (2021)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Lupeol Stearate Accelerates Healing and Prevents Recurrence of Gastric Ulcer in Rodents
por: Somensi, Lincon Bordignon, et al.
Publicado: (2022)

Accelerated Ulcer Healing and Resistance to Ulcer Recurrence with Gastroprotectants in Rat Model of Acetic Acid-induced Gastric Ulcer
por: Young Oh, Tae, et al.
Publicado: (2008)

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP
por: Distrutti, Eleonora, et al.
Publicado: (2014)

Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial
por: Sinha, Anju, et al.
Publicado: (2015)

The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

Royal jelly accelerates healing of acetate induced gastric ulcers in male rats
por: Sofiabadi, Mohammad, et al.
Publicado: (2020)

Extracellular vesicle-derived silk fibroin nanoparticles loaded with MFGE8 accelerate skin ulcer healing by targeting the vascular endothelial cells
por: Luo, Liwen, et al.
Publicado: (2023)

Potential role of probiotics in the management of gastric ulcer
por: KHODER, GHALIA, et al.
Publicado: (2016)

Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study)
por: Ebrahimi-Mameghani, Mehrangiz, et al.
Publicado: (2013)

Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment
por: Dolpady, Jayashree, et al.
Publicado: (2016)

A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
por: Chong, Pui Lin, et al.
Publicado: (2021)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway
por: WANG, Hui, et al.
Publicado: (2019)

The Probiotic VSL#3(®) Does Not Seem to Be Efficacious for the Treatment of Gastrointestinal Symptomatology of Patients with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Calandre, Elena P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ddnf0tqcvj1s0gf3piskqg2qd